Notice of 2026 Interim Results & Webinars

RTW Biotech Opportunities Ltd

01 September 2026

 

LEI: 549300Q7EXQQH6KF7Z84

1 September 2026

RTW Biotech Opportunities Ltd

Notice of 2026 Interim Results & Webinars

RTW Biotech Opportunities Ltd, the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to share that its Interim Results for the six months ended 30 June 2026 will be published on 14 September 2026.

At 10:00 BST on 14 September, RTW Investments' Chief Investment Officer, Rod Wong, and Senior Director of Business & Corporate Development, Oliver Kenyon, will host a webinar via the London Stock Exchange Group's SparkLive platform. The webinar is open to research analysts and existing or potential shareholders. To register your attendance at the webinar, click here.

At 14:00 BST on 22 September, Rod Wong and Oliver Kenyon will host a live Q&A, also via the SparkLive platform. Those interested in attending the Q&A may request a registration link via [e-mail]. Questions may also be submitted during the live Q&A or in advance to the same address.

Enquiries:

RTW Investments, LP - Investment Manager Oliver Kenyon Krisha McCune (Investor Relations)	[phone] [e-mail]
Cadarn Capital - PR & IR Partner Lucy Clark (PR) David Harris (Distribution)	[phone] / [e-mail] [phone] / [e-mail]
Jefferies International Limited - Joint Corporate Broker Gaudi Le Roux Harry Randall-Knowles	[phone]
BofA Securities - Joint Corporate Broker Edward Peel Alex Penney	[phone]
Altum (Guernsey) Limited Joanna Duquemin Nicolle Sadie Morrison	[phone]

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwbio.com for more information.

***********

The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements, as well as those included in any related materials, are subject to risks, uncertainties and assumptions about the Company and/or its underlying investments, including, among other things, the development of the applicable entity's business, trends in its operating industry, expected use of financing proceeds and future capital expenditures and acquisitions. In light of these risks, uncertainties and assumptions, the events in the forward-looking statements may not occur.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

 

END